Innovo Therapeutics' INV-101 has shown positive results in a randomized, double-blind, placebo-controlled study with no serious adverse events (SAEs).

Ocugen’s OCU500, a mucosal COVID-19 vaccine, enters Phase 1 trial; focuses on inhalation and nasal spray administration.

Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting –Favorable safety and tolerability, with ...

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or ...